HB0034 vs spesolimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-36 receptor · full Psoriasis pipeline

HB0034

Developed by Shanghai Huaota Biopharmaceutical Co.

Phase 2/3 in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

spesolimab · Spevigo

Marketed by Boehringer Ingelheim and partners

Approved in Psoriasismonoclonal antibody (anti-IL-36 receptor)
Reliable signal

NCT03782792 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial that enrolled 53 patients against a planned 51, based on a sample-size calculation in the posted protocol. Its primary endpoint, complete clearance of pustules on the physician global assessment at Week 1, was met with a large difference over placebo (risk difference 48.7 percentage points, one-sided p=0.0004).

Next expected readout: September 2027 · NCT03886246 (registry estimate)

Reported efficacy

Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%) (met)

Result source: NCT03782792

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHB0034spesolimab
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

HB0034
—Not reported
spesolimab
—Not reported

PASI 90

HB0034
—Not reported
spesolimab
—Not reported

PASI 100

HB0034
—Not reported
spesolimab
—Not reported

sPGA 0/1

HB0034
—Not reported
spesolimab
—Not reported

DLQI, change

HB0034
—Not reported
spesolimab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HB0034: no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HB0034: 0 of 4 rows · spesolimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricspesolimab
Dropout rate
—900 mg i.v.a
NCT03782792 · Phase 2
show 15 more results
—900 mg i.v.
NCT03782792 · Phase 2
8.6%900 mg i.v. SD
NCT03782792 · Phase 2
—900 mg i.v. SD
NCT03782792 · Phase 2
—Spesolimab IV DD
NCT04399837 · Phase 2
—Spesolimab IV SD
NCT04399837 · Phase 2
—Spesolimab OL SC
NCT04399837 · Phase 2
13.3%Spesolimab SC High Dose
NCT04399837 · Phase 2
12.9%Spesolimab SC Low Dose
NCT04399837 · Phase 2
9.7%Spesolimab SC Medium Dose
NCT04399837 · Phase 2
6.7%double dose
NCT05239039 · Phase 3 · registry result, not featured evidence
0%single dose
NCT05239039 · Phase 3 · registry result, not featured evidence
0%900 mg i.v. SD
NCT05200247 · Phase 3 · registry result, not featured evidence
21.1%BI 655130 High Dose
NCT03135548 · Phase 2 · registry result, not featured evidence
26.3%BI 655130 Low Dose
NCT03135548 · Phase 2 · registry result, not featured evidence
0%
NCT02978690 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—900 mg i.v.a
NCT03782792 · Phase 2
show 15 more results
—900 mg i.v.
NCT03782792 · Phase 2
—900 mg i.v. SD
NCT03782792 · Phase 2
—900 mg i.v. SD
NCT03782792 · Phase 2
—Spesolimab IV DD
NCT04399837 · Phase 2
—Spesolimab IV SD
NCT04399837 · Phase 2
—Spesolimab OL SC
NCT04399837 · Phase 2
—Spesolimab SC High Dose
NCT04399837 · Phase 2
—Spesolimab SC Low Dose
NCT04399837 · Phase 2
—Spesolimab SC Medium Dose
NCT04399837 · Phase 2
—double dose
NCT05239039 · Phase 3 · registry result, not featured evidence
—single dose
NCT05239039 · Phase 3 · registry result, not featured evidence
—900 mg i.v. SD
NCT05200247 · Phase 3 · registry result, not featured evidence
—BI 655130 High Dose
NCT03135548 · Phase 2 · registry result, not featured evidence
—BI 655130 Low Dose
NCT03135548 · Phase 2 · registry result, not featured evidence
—
NCT02978690 · Phase 1 · registry result, not featured evidence
Serious AEs
22.2%900 mg i.v.a
NCT03782792 · Phase 2
show 15 more results
33.3%900 mg i.v.
NCT03782792 · Phase 2
—900 mg i.v. SD
NCT03782792 · Phase 2
17.1%900 mg i.v. SD
NCT03782792 · Phase 2
40%Spesolimab IV DD
NCT04399837 · Phase 2
4.5%Spesolimab IV SD
NCT04399837 · Phase 2
5%Spesolimab OL SC
NCT04399837 · Phase 2
10%Spesolimab SC High Dose
NCT04399837 · Phase 2
15.6%Spesolimab SC Low Dose
NCT04399837 · Phase 2
3.2%Spesolimab SC Medium Dose
NCT04399837 · Phase 2
13.3%double dose
NCT05239039 · Phase 3 · registry result, not featured evidence
4.2%single dose
NCT05239039 · Phase 3 · registry result, not featured evidence
0%900 mg i.v. SD
NCT05200247 · Phase 3 · registry result, not featured evidence
0%BI 655130 High Dose
NCT03135548 · Phase 2 · registry result, not featured evidence
5.3%BI 655130 Low Dose
NCT03135548 · Phase 2 · registry result, not featured evidence
0%
NCT02978690 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
900 mg i.v.a
pustular psoriasis 18.5% (placebo 22.2%)
diarrhoea 11.1% (placebo 0%)
erythema 7.4% (placebo 0%)
NCT03782792 · Phase 2
show 14 more results
900 mg i.v.
pustular psoriasis 33.3% (placebo 22.2%)
pyrexia 33.3% (placebo 22.2%)
vomiting 33.3% (placebo 5.6%)
NCT03782792 · Phase 2
900 mg i.v. SD
pustular psoriasis 48.6% (placebo 22.2%)
headache 11.4% (placebo 5.6%)
nausea 8.6% (placebo 0%)
NCT03782792 · Phase 2
asthenia 10% (placebo 0%)
chest discomfort 10% (placebo 0%)
constipation 10% (placebo 0%)
NCT04399837 · Phase 2
pustular psoriasis 22.7% (placebo 53.3%)
arthralgia 9.1% (placebo 3.3%)
erythema 9.1% (placebo 0%)
NCT04399837 · Phase 2
pustular psoriasis 20% (placebo 53.3%)
upper respiratory tract infection 20% (placebo 13.3%)
urinary tract infection 15% (placebo 0%)
NCT04399837 · Phase 2
injection site erythema 16.7% (placebo 3.3%)
psoriasis 13.3% (placebo 10%)
urinary tract infection 13.3% (placebo 0%)
NCT04399837 · Phase 2
pustular psoriasis 28.1% (placebo 53.3%)
arthralgia 12.5% (placebo 3.3%)
blood creatine phosphokinase increased 12.5% (placebo 6.7%)
NCT04399837 · Phase 2
pustular psoriasis 29% (placebo 53.3%)
upper respiratory tract infection 19.4% (placebo 13.3%)
psoriasis 16.1% (placebo 10%)
NCT04399837 · Phase 2
double dose
covid-19 40%
pyrexia 20%
anaemia 6.7%
NCT05239039 · Phase 3 · registry result, not featured evidence
single dose
upper respiratory tract infection 16.7%
covid-19 12.5%
hyperuricaemia 12.5%
NCT05239039 · Phase 3 · registry result, not featured evidence
900 mg i.v. SD
pustular psoriasis 18.2%
acne 9.1%
chest pain 9.1%
NCT05200247 · Phase 3 · registry result, not featured evidence
nasopharyngitis 42.1% (placebo 38.1%)
headache 31.6% (placebo 33.3%)
palmoplantar pustulosis 15.8% (placebo 19%)
NCT03135548 · Phase 2 · registry result, not featured evidence
nasopharyngitis 26.3% (placebo 38.1%)
headache 21.1% (placebo 33.3%)
arthralgia 15.8% (placebo 4.8%)
NCT03135548 · Phase 2 · registry result, not featured evidence
arthralgia 42.9%
chills 28.6%
eczema 28.6%
NCT02978690 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

spesolimab

GPPGA Pustulation Sub-score 0 0.543% (n=35) vs 0.056% (n=18) placebo @ 1wk900 mg i.v. SD
event count · % of participants
NCT03782792 · Phase 2
show 1 more result
0.514% (n=35) vs 0.111% (n=18) placebo @ 4wk900 mg i.v. SD
NCT03782792 · Phase 2
GPPGA 0 1 0.429% (n=35) vs 0.111% (n=18) placebo @ 1wk900 mg i.v. SD
responder rate · % of participants
NCT03782792 · Phase 2
show 1 more result
0.486% (n=35) vs 0.111% (n=18) placebo @ 4wk900 mg i.v. SD
NCT03782792 · Phase 2
GPPASI 75 0.457% (n=35) vs 0.111% (n=18) placebo @ 4wk900 mg i.v. SD
responder rate · % of participants
NCT03782792 · Phase 2
Pain VAS -22.45 vs NA placebo score @ 4wk900 mg i.v. SD
absolute change · score
NCT03782792 · Phase 2
PSS Total -2 vs NA placebo score @ 4wk900 mg i.v. SD
absolute change · score
NCT03782792 · Phase 2
FACIT-Fatigue 3 vs NA placebo score @ 4wk900 mg i.v. SD
absolute change · score
NCT03782792 · Phase 2
GPPASI 50 0.543% (n=35) vs 0.111% (n=18) placebo @ 4wk900 mg i.v. SD
responder rate · % of participants
NCT03782792 · Phase 2
show 1 more result
0.429% (n=35) vs 0.278% (n=18) placebo @ 1wk900 mg i.v. SD
NCT03782792 · Phase 2
GPPASI -60.5% (n=35) vs NA placebo @ 4wk900 mg i.v. SD
percent change · % of baseline
NCT03782792 · Phase 2
show 1 more result
-42.8% (n=35) vs 1.02% (n=18) placebo @ 1wk900 mg i.v. SD
NCT03782792 · Phase 2
Time to Flare NA vs 8.61 placebo months
time to event · months
NCT04399837 · Phase 2
show 2 more results
NA vs 8.61 placebo months
NCT04399837 · Phase 2
NA vs 8.61 placebo months
NCT04399837 · Phase 2
Disease Flare 0.226% (n=31) vs 0.516% (n=31) placebo @ 48wk
event count · % of participants
NCT04399837 · Phase 2
show 2 more results
0.297% (n=31) vs 0.516% (n=31) placebo @ 48wk
NCT04399837 · Phase 2
0.127% (n=30) vs 0.516% (n=31) placebo @ 48wk
NCT04399837 · Phase 2
Time to Worsening Symptoms NA vs 3.69 placebo months
time to event · months
NCT04399837 · Phase 2
show 2 more results
NA vs 3.69 placebo months
NCT04399837 · Phase 2
NA vs 3.69 placebo months
NCT04399837 · Phase 2
Time to DLQI Worsening 8.26 vs 3.69 placebo months
time to event · months
NCT04399837 · Phase 2 · converted to months from 35.8 weeks as posted
show 2 more results
11.38 vs 3.69 placebo months*
NCT04399837 · Phase 2 · converted to months from 49.3 weeks as posted
NA vs 3.69 placebo months
NCT04399837 · Phase 2

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0034's landscape · spesolimab's landscape